Education
About Us
Working with TipRanks
Follow Us
Kairos Pharma, Ltd. (KAPA)
:KAPA
Total Valuation
Kairos Pharma, Ltd. has a market cap or net worth of $15.39M. The enterprise value is ―.
Market Cap$15.39M
Enterprise Value―
Share Statistics
Kairos Pharma, Ltd. has 20,821,354 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding20,821,354
Owned by Insiders32.20%
Owned by Institutions0.40%
Financial Efficiency
Kairos Pharma, Ltd.’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -49.06%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-49.06%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-2.60M
Employee Count1
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Kairos Pharma, Ltd. is ―. Kairos Pharma, Ltd.’s PEG ratio is -0.19.
PE Ratio―
PS Ratio0.00
PB Ratio3.61
Price to Fair Value3.61
Price to FCF-4.36
Price to Operating Cash Flow-4.05
PEG Ratio-0.19
Income Statement
In the last 12 months, Kairos Pharma, Ltd. had revenue of 0.00 and earned -2.60M in profits. Earnings per share was -0.23.
Revenue0.00
Gross Profit-160.00K
Operating Income-2.34M
Pretax Income-2.60M
Net Income-2.60M
EBITDA-1.58M
Earnings Per Share (EPS)-0.23
Cash Flow
In the last 12 months, operating cash flow was -4.16M and capital expenditures 838.00K, giving a free cash flow of -3.32M billion.
Operating Cash Flow-4.16M
Free Cash Flow-3.32M
Free Cash Flow per Share-0.16
Dividends & Yields
Kairos Pharma, Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change-56.80%
50-Day Moving Average0.94
200-Day Moving Average0.95
Relative Strength Index (RSI)38.00
Average Volume (3m)1.08M
Important Dates
Kairos Pharma, Ltd. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Kairos Pharma, Ltd. as a current ratio of 4.20, with Debt / Equity ratio of 0.00%
Current Ratio4.20
Quick Ratio4.20
Debt to Market Cap0.00
Net Debt to EBITDA0.54
Interest Coverage Ratio-2.73
Taxes
In the past 12 months, Kairos Pharma, Ltd. has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kairos Pharma, Ltd. EV to EBITDA ratio is -6.82, with an EV/FCF ratio of -4.04.
EV to Sales0.00
EV to EBITDA-6.82
EV to Free Cash Flow-4.04
EV to Operating Cash Flow-4.04
Balance Sheet
Kairos Pharma, Ltd. has $5.58M in cash and marketable securities with $0.00 in debt, giving a net cash position of $5.58M billion.
Cash & Marketable Securities$5.58M
Total Debt$0.00
Net Cash$5.58M
Net Cash Per Share$0.27
Tangible Book Value Per Share$0.40
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kairos Pharma, Ltd. is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.00
Price Target Upside995.89% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―